Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM)

NCT03018288 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

90

Enrollment

NIH

Sponsor class

Stopped Study closed early due to poor accrual.

Conditions

Glioblastoma

Interventions

DRUG: Pembrolizumab
BIOLOGICAL: HSPPC-96
DRUG: Temozolomide
OTHER: Placebo
PROCEDURE: Surgery

Sponsor

National Cancer Institute (NCI)